Everest Medicines (HKSE:01952) Days Sales Outstanding : 39.52 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Days Sales Outstanding?

Everest Medicines's average Accounts Receivable for the six months ended in Dec. 2023 was HK$27.7 Mil. Everest Medicines's Revenue for the six months ended in Dec. 2023 was HK$128.0 Mil. Hence, Everest Medicines's Days Sales Outstanding for the six months ended in Dec. 2023 was 39.52.

The historical rank and industry rank for Everest Medicines's Days Sales Outstanding or its related term are showing as below:

HKSE:01952' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.11 Med: 79.97 Max: 331.82
Current: 54.11

During the past 6 years, Everest Medicines's highest Days Sales Outstanding was 331.82. The lowest was 54.11. And the median was 79.97.

HKSE:01952's Days Sales Outstanding is ranked better than
65.77% of 888 companies
in the Biotechnology industry
Industry Median: 72.665 vs HKSE:01952: 54.11

Everest Medicines's Days Sales Outstanding declined from Dec. 2022 (45.84) to Dec. 2023 (39.52).

Everest Medicines Days Sales Outstanding Historical Data

The historical data trend for Everest Medicines's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Days Sales Outstanding Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

331.82

75.16

79.97

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial					165.91	61.73	45.84	63.07	39.52

Competitive Comparison of Everest Medicines's Days Sales Outstanding

For the Biotechnology subindustry, Everest Medicines's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Days Sales Outstanding falls into.

Everest Medicines Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Everest Medicines's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (5.823	+	54.534)	/	2 )	/	137.742	*	365
=	30.1785					/	137.742	*	365
=	79.97

Everest Medicines's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.901	+	54.534)	/	2 )	/	128.013	*	365 / 2
=	27.7175					/	128.013	*	365 / 2
=	39.52

Everest Medicines (HKSE:01952) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Everest Medicines Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines